Patent US3989833A successfully refreshed from Google Patents.
US3989833A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions containing adenine derivatives
Assignee: Merck Patent GmbH
•
Filing: 1974-11-04
•
Granted: 1976-11-02
•
Expires: 1994-11-04
Abstract
Abstract Adenine derivatives of the formula ##SPC1## Wherein R is phenyl or thienyl, and the physiologically acceptable acid addition salts thereof, possess, with good compatibility, cardio-active properties and are produced by the reaction of a purine derivative of the formula ##SPC2## Wherein X is F, Cl, Br, I, SR 1 , SOR 1 , SO 2 R 1 or OSi(CH 3 ) 3 , R 1 being alkyl of 1-4 carbon atoms, phenyl or benzyl, with an amine of the formula ##SPC3## Wherein R has the values given above, or a salt thereof.
Inventors
- 👤 Rochus Jonas
- 👤 Werner Mehrhof
- 👤 Karl Heinz Becker
- 👤 Hans-Jochen Schliep
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 20:47
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/519; A61K31/52; A61K31/522; A61K9/00; A61K9/20; A61K9/2004; A61K9/2022; A61K9/205; A61K9/2054; C; C07; C07D; C07D473/00; C07D473/26; C07D473/32; C07D473/34
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
58 words
A pharmaceutical composition adapted for oral administration in the form of tablets, dragees, capsules, a syrup or an elixir and comprising, in admixture with a pharmaceutically acceptable carrier, from 3 to 500 mg. per unit dosage of an adenine derivative of the formula ##SPC8## wherein R is phenyl or thienyl, or a physiologically acceptable acid addition salt thereof.
Claim 2
Dependent Claim
58 words
A pharmaceutical composition adapted for oral administration in the form of tablets, dragees, capsules, a syrup or an elixir and comprising, in admixture with a pharmaceutically acceptable carrier, from 3 to 500 mg. per unit dosage of an adenine derivative of the formula ##SPC8## wherein R is phenyl or thienyl, or a physiologically acceptable acid addition salt thereof.
Claim 3
Dependent Claim
10 words
A composition of claim 1, wherein the adenine derivative N(6)-[3-(thienyl-2)-bicyclo[2,2,2]octyl-2]-adenine.
Claim 4
Dependent Claim
10 words
A composition of claim 1, wherein the adenine derivative N(6)-[3-(thienyl-3)-bicyclo[2,2,2]octyl-2]-adenine.
Claim 5
Dependent Claim
10 words
A composition of claim 1, wherein the adenine derivative N(6)-[3-phenylbicyclo[2,2,2]-octyl-2]-adenine.
Claim 6
Dependent Claim
10 words
A composition of claim 1 in the form of dragees.
Claim 7
Dependent Claim
8 words
A composition of claim 1 in tablet form.
Claim 8
Independent Claim
54 words
A method for the treatment of intravascular pain in humans which comprises administering to a human suffering therefrom an amount from 3 to 500 mg. per dosage of an adenine derivative of the formula ##SPC9## wherein R is phenyl or thienyl, or a physiologically acceptable acid addition salt thereof effective to ameliorate the pain.
Claim 9
Independent Claim
54 words
A method for the treatment of intravascular pain in humans which comprises administering to a human suffering therefrom an amount from 3 to 500 mg. per dosage of an adenine derivative of the formula ##SPC9## wherein R is phenyl or thienyl, or a physiologically acceptable acid addition salt thereof effective to ameliorate the pain.
References Cited (Backward Citations)
US3838147A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-11-02 | 1980-05-03 | 1980-11-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-11-02 | 1984-05-03 | 1984-11-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-11-02 | 1988-05-03 | 1988-11-02 | $7700.00 | Window Closed / Lapsed |